---
title: "Medley Posts Strong Revenue Growth but Quarterly Loss, Reaffirms Robust 2026 Outlook"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286216000.md"
description: "Medley reported a 25.2% increase in consolidated net sales to ¥10.19 billion for Q1 2026, with EBITDA rising 48.1% to ¥631 million. However, the company faced a slight operating loss of ¥67 million and a net loss of ¥62 million. Despite these losses, Medley reaffirmed its 2026 outlook, projecting 26.1% sales growth and an 84.5% increase in profit to ¥1.8 billion. The company maintains a no-dividend policy, focusing on reinvestment, while analysts rate the stock as a Buy with a target price of ¥4500.00."
datetime: "2026-05-13T07:32:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286216000.md)
  - [en](https://longbridge.com/en/news/286216000.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286216000.md)
---

# Medley Posts Strong Revenue Growth but Quarterly Loss, Reaffirms Robust 2026 Outlook

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Medley ( (JP:4480) ) has issued an update.

Medley reported consolidated net sales of ¥10.19 billion for the quarter ended March 31, 2026, up 25.2% year on year, with EBITDA rising 48.1% to ¥631 million but a slight operating loss of ¥67 million and a net loss attributable to owners of the parent of ¥62 million. Total assets increased to ¥43.68 billion while the equity ratio declined to 29.9% amid higher treasury share holdings, and the company maintained a no-dividend policy but reaffirmed its full-year 2026 forecast, projecting 26.1% net sales growth and an 84.5% jump in profit attributable to owners of the parent to ¥1.8 billion, signaling confidence in its growth trajectory despite near-term losses.

For full-year 2026, Medley expects EBITDA of ¥5.8 billion, operating profit of ¥2.95 billion, and ordinary profit of ¥3.25 billion, underscoring its view that current investments will translate into stronger profitability. The unchanged guidance suggests that management sees no material deterioration in business conditions and aims to solidify its position in the digital healthcare market, although the lower equity ratio and continued absence of dividends highlight a focus on reinvestment and balance sheet flexibility over immediate shareholder payouts.

The most recent analyst rating on (JP:4480) stock is a Buy with a Yen4500.00 price target. To see the full list of analyst forecasts on Medley stock, see the JP:4480 Stock Forecast page.

**More about Medley**

Medley, Inc., listed on the Tokyo Stock Exchange under code 4480, operates in the technology-enabled healthcare and human resources services space. The company generates consolidated net sales primarily from digital medical and related platforms, and it targets growth in Japan by expanding its service offerings and customer base across the healthcare ecosystem.

**Average Trading Volume:** 453,099

**Technical Sentiment Signal:** Hold

**Current Market Cap:** Yen70.91B

### Related Stocks

- [4480.JP](https://longbridge.com/en/quote/4480.JP.md)

## Related News & Research

- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [These 3 engineering roles are now converging, says EY's AI leader](https://longbridge.com/en/news/286538922.md)
- [Endeavour Announces Results of Annual General Meeting 2026 | EDVMF Stock News](https://longbridge.com/en/news/287245296.md)
- [JAC Recruitment (TSE:2124) EPS Jump In Q1 2026 Tests Cautious Market Narratives](https://longbridge.com/en/news/286545331.md)
- [Assessing Shizuoka Financial Group (TSE:5831) Valuation After FY 2026 Results And Board Leadership Review](https://longbridge.com/en/news/286786560.md)